Aspen Pharmacare Holdings (JSE:APN) Total Receivables: R10,069 Mil (As of Dec. 2025)


JSE:APN Aspen Pharmacare Holdings Ltd JSE:APN
74 GF Score
Price R151.05
GF Value R170.74
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Total Receivables?

Aspen Pharmacare Holdings JSE:APN +2.70% 74 Total Receivables is R10,069 Mil as of Dec. 2025. GuruFocus rates JSE:APN with a GF Score™ of 74/100 and a GF Value™ of R170.74 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Aspen Pharmacare Holdings's Total Receivables for the quarter that ended in Dec. 2025 was R10,069 Mil.

Aspen Pharmacare Holdings Total Receivables Related Terms

Aspen Pharmacare Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for Aspen Pharmacare Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspen Pharmacare Holdings Total Receivables Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,002.00 9,612.00 11,443.00 11,465.00 12,069.00

Aspen Pharmacare Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,556.00 11,465.00 13,341.00 12,069.00 10,069.00
JSE:APN
74GF Score
Aspen Pharmacare Holdings Ltd JSE:APN
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspen Pharmacare Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of R10,069 Mil mean?
Aspen Pharmacare Holdings (JSE:APN) has a Total Receivables of R10,069 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aspen Pharmacare Holdings and its competitors.
Is Aspen Pharmacare Holdings' Total Receivables too high?
Aspen Pharmacare Holdings' current Total Receivables is R10,069 Mil. Overall, Aspen Pharmacare Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Total Receivables compare to ZTS and UTHR?
Aspen Pharmacare Holdings' Total Receivables of R10,069 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aspen Pharmacare Holdings and its competitors. Aspen Pharmacare Holdings's current Total Receivables is R10,069 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R170.74, compared to a current price of R151.05 — trading 11.5% below its estimated fair value. The current Total Receivables is R10,069 Mil. Aspen Pharmacare Holdings' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Total Receivables is R10,069 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of R151.05 is trading 11.5% below its estimated GF Value™ of R170.74. GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.

Key valuation signals for JSE:APN:

  • Total Receivables: R10,069 Mil
  • GF Value™: R170.74 vs. price of R151.05 (11.5% below fair value)
  • GF Score™: 74/100 with 10 warning signs

No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
74GF Score

Get the complete analysis for JSE:APN

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R151.05
Price
R170.74
GF Value